28-30 September, 2016 - Budapest, Hungary

Registration Open

Emerging Diseases in Animals:
Strategies in Surveillance, Control and Eradication

Budapest, Hungary
28 - 30 September 2016

Budapest, Hungary

REGISTER HERE

Emerging animal diseases challenge the health of domestic and wild animals. These highly contagious or transmissible diseases may spread easily, irrespective of political and geographic borders. This spread is fostered by the increased global movement of domestic animals and food produced from animals, as well as by vectors such as man, wild animals, intermediate hosts, and contaminated materials of all kind. This spread is also influenced by other factors such as changes in climate.

Outbreaks of diseases in livestock have a negative impact on economies, individuals’ livelihood and quality of life, as well as global safety of food produced by animals.

Although there is permanent progress in the development of new vaccines against a wide range of diseases, emerging infections and transboundary spread pose specific challenges in terms of surveillance and prophylactic interventions.

The goal of this meeting, to be held in 2016, is to update current experience in the identification, tracking, and control of these animal diseases. This includes experience thus far with licensing of vaccines required for emergency situations or scenarios. An additional area of discussion will focus on fostering rapid availability of vaccines.

More information and registration here.

11-12 October, 2016 - USP, Rockille, Maryland

Registration Open

3rd Statistical and Data Management Approaches
for Biotechnology Drug Development

USP Headquarters, Rockville, Maryland
October 11-12, 2016

Co-organized by IABS and FDA

REGISTER HERE

The 3rd annual stats & data management meeting will bring together regulators, and scientists, or those interested in statistics from academia and industry, who have a background in statistics, to continue exploring how best to resolving existing challenges in ensuring the quality of biotechnology medicinal products and to bring high quality medicines to patients. Guidance on how to use statistics for a variety of activities required during biotechnology product development such as method development, improvement and replacement, product comparability, biosimilarity exercises and stability program development will be provided by the speakers and panel members. In addition, the complexity of the types of data and the volume being analysed is ever increasing and how best to manage such data will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.

More information and registration here.

November 2-3, 2016 - London, United Kingdom

Registration Open

CELL THERAPY 2016

November 2-3, 2016
The Wellcome Collection
London, United Kingdom

REGISTER HERE

The 2016 Cell Therapy conference will identify the key issues to be addressed for the manufacture of cell therapies and provide scientific consensus on selected aspects to inform the drafting of future guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.

It is intended that the conference output should provide core elements that will be useful in establishing international consensus on the requirements for manufacture of cell based medicines and enable progress towards a potential future WHO endorsed guidance.

More information and registration here.

21-22 March, 2017 - Geneva, Switzerland

Save The Date

Future Development and Scientific Considerations of Biotechnology Reference Standards

co-organized by IABS and IFPMA March 21-22, 2017
Centre International de Conférences Geneva, Switzerland

Goal and outcomes of the meeting

The goal of the meeting is to discuss the current relevance and scientific utility of biological reference standards in the development of biotechnology products, biosimilars and biological assays. Biological reference standards can take the form of in-house manufacturer’s standards, World Health International Standards, NIBSC reference reagents, Pharmacopoeia standards and other public standards such as NIST standards. The ways in which these material are used, how they are calibrated and the use of any associated unitages will be discussed. The scientific and regulatory considerations for the creation and use of these materials will also be included.

More information coming soon

2nd Human Challenge Trials Conference - Rockville, Maryland

Save The Date

2nd Human Challenge Trials Workshop
US Pharmacopeia - Rockville, Maryland
March 15-17, 2017

Our world needs safer, more effective drugs and vaccines to prevent and treat infectious diseases.  Controlled human infections (CHIs) have served as an effective tool to promote this objective. For example, CHIs have led to progress in developing interventions against respiratory pathogens, enteric pathogens, and parasites. The most frequent application is the conduct of human challenge trials (HCTs), which can safely assess the value of novel or improved drugs and vaccines much more rapidly and efficiently than field trials, particularly if efficacy against CHI bridges to the field.  Progress against an infectious threat is greatly hampered when the field lacks a supporting human challenge model, such as is the case for human immunodeficiency virus and Mycobacterium tuberculosis.

Based on the premise that optimal use of CHIs is one of the best, most efficient ways to achieve rapid progress against infectious diseases, IABS is hosting a workshop to review the use of HCTs to promote the development of new drugs and vaccines, the benefits and risks of this approach, the regulatory framework within which HCTs are conducted, and novel CHI applications that would open new translational pathways.  This workshop follows two and a half years after the first such workshop hosted by IABS in Strasbourg, France, September 2014.

More information about this work coming soon.